http://ift.tt/eA8V8J
Interpace Diagnostics’ use of microRNAs for distinguishing benign from malignant thyroid neoplasms has been patented in the EU
April 03, 2017 at 08:55PM
http://ift.tt/2nT07Rh
from
http://ift.tt/2nT07Rh
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment